Skip to main content

Month: September 2021

Dimensional Fund Advisors Ltd. : Form 8.3 – STAGECOACH GROUP PLC – Ordinary Shares

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser:   Dimensional Fund Advisors Ltd. (“Dimensional”), in its capacity as investment manager and on behalf its affiliates who are also investment managers. Dimensional and its affiliates expressly disclaim beneficial ownership of the shares described in this form 8.3(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.    (c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate...

Continue reading

Luckin Coffee Announces Launch of Scheme of Arrangement in Compliance with RSA

Scheme Related to Restructuring of Convertible Senior Notes Due 2025 BEIJING, Sept. 21, 2021 (GLOBE NEWSWIRE) — Luckin Coffee Inc. (in Provisional Liquidation) (“Luckin Coffee” or the “Company”) (OTC: LKNCY) today announced that it has filed a petition and summons for directions in the Grand Court of the Cayman Islands (the “Cayman Court”) regarding a scheme of arrangement (the “Scheme”) related to the restructuring of its $460 million 0.75% Convertible Senior Notes due 2025 (the “Existing Notes”) proposed by Luckin Coffee and its Joint Provisional Liquidators.1 Pursuant to the summons for directions, the Company seeks an order for the convening of a single meeting of the class of creditors affected by the Scheme (the “Scheme Creditors”) to consider and, if thought fit, approve, with or without modification, the Scheme (the “Convening...

Continue reading

Dimensional Fund Advisors Ltd. : Form 8.3 – NATIONAL EXPRESS GROUP PLC – Ordinary Shares

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser:   Dimensional Fund Advisors Ltd. (“Dimensional”), in its capacity as investment manager and on behalf its affiliates who are also investment managers. Dimensional and its affiliates expressly disclaim beneficial ownership of the shares described in this form 8.3(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.    (c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate...

Continue reading

Offer update – close of early bird discount

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY JURISDICTION FOR WHICH THE SAME COULD BE UNLAWFUL. THE INFORMATION CONTAINED HEREIN DOES NOT CONSTITUTE AN OFFER OF SECURITIES FOR SALE IN ANY JURISDICTION, INCLUDING IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA. HARGREAVE HALE AIM VCT PLC LEI: 213800LRYA19A69SIT31         21 September 2021 Offer update – close of early bird discount The Board of Hargreave Hale AIM VCT plc (the “Company”) announced on 2 September 2021 that the Company had published a prospectus in relation to an offer for subscription to raise up to £20 million, together with an over-allotment facility to raise up to a further £20 million (the “Offer”). Under the Offer,...

Continue reading

Arbutus Appoints Lisa M. Caperelli as Vice President, Investor Relations

WARMINSTER, Pa., Sept. 21, 2021 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced the Company has appointed Lisa M. Caperelli to the newly created position of Vice President of Investor Relations, leading investor relations strategy and communications activities, reporting to David Hastings, Arbutus’ Chief Financial Officer. “We are excited to welcome Lisa to the management team as she brings a wealth of experience in running highly effective investor relations and communications programs in the life sciences industry,” commented David Hastings. “We...

Continue reading

Pacira Announces Publication of Phase 3 Study of EXPAREL Infiltration in Pediatric Patients Undergoing Spinal or Cardiac Surgeries

Study demonstrating safety and tolerability of EXPAREL published in Journal of Clinical Anesthesia PARSIPPANY, N.J., Sept. 21, 2021 (GLOBE NEWSWIRE) — Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced that full results of its Phase 3 PLAY study of EXPAREL® (bupivacaine liposome injectable suspension) administered via infiltration in pediatric patients undergoing spinal or cardiac surgeries have been published in Journal of Clinical Anesthesia. The study, which was designed to establish the safety and pharmacokinetics (PK) of EXPAREL in a pediatric population, found the PK profile was comparable across age groups and generally consistent with the profile in adult patients. No safety concerns were identified at a dose of 4 mg/kg. Key findings include:The safety of EXPAREL was comparable to bupivacaine and consistent across...

Continue reading

NFI schedules third quarter 2021 financial results release and conference call

WINNIPEG, Manitoba, Sept. 21, 2021 (GLOBE NEWSWIRE) — (TSX: NFI, OTC: NFYEF) NFI Group Inc. (“NFI” or the “Company”), a leading independent bus and coach manufacturer and a leader in electric mass mobility solutions, today announced that it intends to release its third quarter 2021 financial results on Wednesday, November 3, 2021 prior to market open. A conference call for analysts and interested listeners will be held on November 3, 2021, at 8:00 a.m. Eastern Time (ET). The call-in number for listeners is 661-567-1097 or 833-562-0121, passcode number 5466715. An accompanying results presentation will be available prior to the call at: www.nfigroup.com A live webcast of the call and presentation will also be available at: https://edge.media-server.com/mmc/p/7tqjksxw A replay of the call will be accessible from 11:00 a.m. ET on...

Continue reading

Progenity to Participate in 11th Annual Partnership Opportunities in Drug Delivery Conference

SAN DIEGO, Sept. 21, 2021 (GLOBE NEWSWIRE) — Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced today that the company will participate in the 11th annual Partnership Opportunities in Drug Delivery (PODD) Conference, October 28-29, 2021 in Boston. Progenity’s Vice President of Strategy and Operations, Chris Wahl, MD, MBA, will participate in the panel titled “Orally Ingestible Devices for Biologics Delivery” on Friday, October 29, at 9:35 a.m. ET. The panel discussion will be live-streamed and will be available on demand for three months following the conference to registered attendees. The session will explore oral delivery of biologics and the many technological approaches currently under investigation and showing promising results, including Progenity’s Oral Biotherapeutic Delivery System (OBDS),...

Continue reading

Luckin Coffee Enters into Binding Term Sheet to Settle U.S. Securities Class Action

BEIJING, Sept. 21, 2021 (GLOBE NEWSWIRE) — Luckin Coffee Inc. (in Provisional Liquidation) (“Luckin Coffee” or the “Company”) (OTC: LKNCY) today announced that it has entered into a binding term sheet (the “Term Sheet”) with the Lead Plaintiffs in the provisionally certified class action In re Luckin Coffee Inc. Securities Litigation, Case No.1:20-cv-01293-JPC-JLC (SDNY) (the “Class Action”) to fully resolve all claims that have been or could be filed on behalf of a class of purchasers of the Company’s ADS between May 17, 2019 through July 15, 2020, inclusive, that has been certified for settlement purposes. Pursuant to the Term Sheet, the settlement is subject to entering into definitive documentation and obtaining approvals from the Cayman Court in the first instance (who has oversight of the provisional liquidation proceedings),...

Continue reading

Ribbon Cutting Ceremony Celebrates Opening of First Citrus Bank in the Heart of Downtown St. Petersburg

First Citrus Bank Celebrates National Small Business Week in St. Pete with Ribbon Cutting and Community-Driven CampaignFirst Citrus Bank St Pete Ribbon CuttingJack Barrett, President & CEO of First Citrus Bank along with Chris Steinocher, President & CEO of St Pete Chamber and other First Citrus Bank associates and board members cutting ribbon for new First Citrus Bank St Pete location.TAMPA, Fla., Sept. 21, 2021 (GLOBE NEWSWIRE) — First Citrus Bank, the St. Petersburg Chamber of Commerce, St. Pete Greenhouse, and the St. Petersburg Area Economic Development Corporation held a ribbon cutting ceremony on Thursday, September 16th, to officially celebrate the opening of the newest First Citrus Bank branch located in the heart of downtown St. Pete at 300 1st Ave S. National Small Business Week was an ideal...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.